The MAP4K5 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the human MAP4K5 gene. Derived from the Raji B lymphocyte cell line, these polyclonal cells harbor a disrupted MAP4K5 locus introduced via CRISPR/Cas9-mediated gene targeting, providing a heterogeneous pool of edited cells for investigating MAP4K5-dependent signaling processes. This product enables researchers to interrogate the functional role of MAP4K5 in a B cell context without the need for single-cell cloning, facilitating robust and reproducible experimental analyses.
The parental Raji cell line is a well-characterized human Burkitt’s lymphoma-derived B lymphocyte model, maintained in suspension culture. These cells are Epstein-Barr virus (EBV)-positive and retain features of mature B cells, including surface immunoglobulin expression and the capacity for antigen presentation. Raji cells are widely employed in immunology and cancer research to study B cell activation, lymphomagenesis, and immune surveillance mechanisms. Their rapid proliferation and genetic tractability make them an ideal host for CRISPR/Cas9-mediated gene disruption, allowing dissection of B cell-intrinsic signaling pathways.
MAP4K5 encodes a serine/threonine kinase of the STE20 family that functions as a critical upstream activator of the c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) cascades. In response to stimuli such as tumor necrosis factor-alpha (TNF-??), interleukin-1 (IL-1), cellular stress, or the small GTPases Rac1 and Cdc42, MAP4K5 is activated and interacts with adaptor proteins TRAF2, JIP1, and JIP2. It then phosphorylates the MAP2Ks MKK4 and MKK7, which in turn activate JNK, leading to phosphorylation of transcription factors c-Jun and ATF2. Simultaneously, MAP4K5 phosphorylates MKK3 and MKK6, activating p38 MAPK, which targets ATF2 and MAPKAPK2. This dual activation modulates gene expression, apoptosis, and inflammatory responses, and also feeds into the NF-??B pathway via crosstalk mechanisms.
In the context of Raji B cells, MAP4K5-mediated signaling is poised to regulate critical B cell functions, including cytokine responsiveness, stress adaptation, and survival. Dysregulation of JNK and p38 MAPK pathways is implicated in B cell lymphomas and autoimmune disorders, making this knockout model valuable for exploring the contribution of MAP4K5 to lymphomagenesis and aberrant immune activation. By ablating MAP4K5 expression in an EBV-positive B lymphocyte background, researchers can assess how loss of this kinase alters downstream signaling events, gene expression programs, and cellular phenotypes under both basal and stimulated conditions, thereby clarifying its role in B cell pathology.
This MAP4K5 knockout polyclonal cell pool supports diverse experimental needs. Researchers can confirm target depletion by western blotting and assess JNK/p38 phosphorylation via phospho-specific antibodies or flow cytometry. Transcriptional profiling via RT-qPCR or RNA-seq, along with functional readouts such as apoptosis and proliferation assays by flow cytometry, cytokine stimulation experiments, and NF-??B/AP-1 reporter assays, allow comprehensive phenotypic characterization. The cells are ideal for drug target validation and dissection of MAPK signaling in B cell models of lymphoma and inflammation. For further details, contact Ascent Research.
